If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) is conditionally approved by the Hong Kong Department of Health for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
PAXLOVID™ (nirmatrelvir tab; ritonavir tab)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
PAXLOVID™ Quick Finder
Did you find an answer to your question?
Yes
No
Resources
Report Adverse Event
Please visit www.pfizersafetyreporting.com to report or contact us at (+852) 2811 9711